Tocilizumab plus glucocorticoids in severe and critically COVID-19 patients. A single center experience
Med Clin (Barc). 2020 Nov 13;155(9):410-411.
doi: 10.1016/j.medcli.2020.07.001.
Epub 2020 Jul 9.
[Article in
English,
Spanish]
Affiliations
- 1 Intensive Care Unit, Centro Médico Teknon, Quironsalud, Barcelona, Spain; Facultad de Ciencias de la Salud, Universidad Nacional del Este (FACISA-UNE), Paraguay. Electronic address: gustavo.jimenezb@quironsalud.es.
- 2 Intensive Care Unit, Centro Médico Teknon, Quironsalud, Barcelona, Spain.
No abstract available
Publication types
-
Case Reports
-
Observational Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Antibodies, Monoclonal, Humanized / therapeutic use*
-
Bacterial Infections / epidemiology
-
Betacoronavirus*
-
COVID-19
-
COVID-19 Drug Treatment
-
Combined Modality Therapy
-
Comorbidity
-
Coronavirus Infections / complications
-
Coronavirus Infections / drug therapy*
-
Coronavirus Infections / epidemiology
-
Coronavirus Infections / therapy
-
Critical Illness / therapy*
-
Cytokine Release Syndrome / drug therapy*
-
Cytokine Release Syndrome / etiology
-
Diabetes Mellitus / epidemiology
-
Female
-
Humans
-
Hypertension / epidemiology
-
Length of Stay / statistics & numerical data
-
Male
-
Methylprednisolone / therapeutic use*
-
Middle Aged
-
Oxygen Inhalation Therapy
-
Pandemics
-
Pneumonia, Viral / complications
-
Pneumonia, Viral / drug therapy*
-
Pneumonia, Viral / epidemiology
-
Pneumonia, Viral / therapy
-
Respiration, Artificial
-
SARS-CoV-2
-
Superinfection / epidemiology
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal, Humanized
-
tocilizumab
-
Methylprednisolone